Ile zarabia pharma R&D w DACH 2026?
Pharma R&D w DACH płaci od postdoc (60.000–75.000 €) do head of research (220.000–320.000 €). Discovery research obejmuje target identification, lead optimisation, medicinal chemistry, in vitro/in vivo pharmacology. Preclinical i translational research jest mostem do kliniki (PK/PD, toxicology, biomarkers). PhD wymagany w 90%+ ról senior. Najwyższe zagęszczenie: Bazylea (Roche, Novartis), Penzberg (Roche), Mannheim (Roche), Wuppertal (Bayer), Ingelheim (Boehringer), Darmstadt (Merck KGaA), Biberach (Boehringer), Berlin (Bayer Research), Moguncja (BioNTech).
Co naprawdę obejmuje pharma R&D
Pharma R&D dzieli się na kilka faz z różnymi funkcjami i profilami. Discovery research: target identification (genomics, proteomics, AI/ML), target validation (CRISPR screens, knock-out models), lead identification (high-throughput screening, fragment-based drug discovery), lead optimisation (medicinal chemistry, structure-based drug design). Preclinical research: in vitro pharmacology, in vivo pharmacology, ADME, pharmacokinetics / pharmacodynamics (PK/PD), toxicology (GLP), bioanalytics. Translational research: biomarker discovery, companion diagnostics, patient stratification, translational medicine. Computational R&D: bioinformatics, cheminformatics, AI/ML drug discovery, molecular modelling, systems biology. CMC development: formulation development, process development, analytical development, stability studies.
Kto rekrutuje pharma R&D w DACH
Big Pharma R&D hubs w DACH: Roche (Bazylea HQ, Penzberg, Mannheim), Novartis (Bazylea HQ, Wehr), Boehringer Ingelheim (Ingelheim, Biberach), Bayer (Berlin, Wuppertal, Leverkusen), Merck KGaA (Darmstadt), Sanofi (Frankfurt), AstraZeneca (Goteborg, Cambridge plus DACH translational), GSK (Stevenage, Wavre plus DACH sites), Pfizer (Sandwich/UK, Cambridge/USA plus DACH affiliates). Specialty biotech: BioNTech (Moguncja), Curevac (Tübingen), MorphoSys (Planegg/Monachium), Evotec (Hamburg), Adagio Therapeutics, BioMed X (Heidelberg), Cardurion. Generyki/biosimilar R&D: Hexal/Sandoz Biosimilar, Stada Specialty Pharma, Mylan/Viatris Biosimilar. CRO z R&D services: Evotec, Charles River Laboratories, Eurofins Discovery, Selvita, Sygnature Discovery, Aragen Bio. Partnerstwa academia-industry: Max Planck Institutes, Helmholtz, EMBL Heidelberg, Charité Berlin.
Pasma wynagrodzeń pharma R&D DACH 2026
Industry postdoc 60.000–75.000 €. Junior scientist (PhD) 75.000–90.000 €, scientist II 90.000–110.000 €, senior scientist 110.000–135.000 €. Principal scientist 135.000–165.000 €. Group leader / lab head 165.000–205.000 €. Senior group leader / distinguished scientist 205.000–255.000 €. Department head (research) 230.000–290.000 €. Vice president research 280.000–380.000 €. Head of research (country lub therapy area) 250.000–320.000 €. Global head of research 320.000–500.000 €+ plus znaczące stock awards. AI/ML w drug discovery, ATMP R&D, onkologia i rare disease płacą 15–25% premium. Bonus 15–30%, stock awards/RSUs w spółkach US standard.
Ukryty rynek pracy R&D
Junior scientist i scientist II w 50–60% widoczne (LinkedIn, Naturejobs, Sciencecareers, portale karierowe pharma). Senior scientist i principal scientist w 60–70% ukryte — wyspecjalizowani headhunters (Quanta Consultancy, Real Staffing R&D, Hays Life Sciences R&D, ProClinical Science, Klein Hersh). Group leader i department head w 80–90% ukryte — Egon Zehnder, Russell Reynolds, Heidrick & Struggles, Spencer Stuart, Klein Hersh. VP research i global head research praktycznie całkowicie ukryte. Hot areas: AI/ML drug discovery, gen therapy, cell therapy, mRNA, radiopharmaceuticals, antibody-drug conjugates.
Šcieżki kariery pharma R&D w DACH
Standardowa ścieżka academia-to-industry: PhD (3–5 lat) → postdoc (2–3 lata industry lub academia) → junior scientist pharma → scientist II (2–3 lata) → senior scientist (3–5 lat) → principal scientist lub group leader → department head → VP research. Ruchy R&D ↔ clinical development w translational research i biomarker rolach standardem. AI/ML, bioinformatics i computational R&D kariery są krótsze — z PhD plus 3–5 lat pharma group leader role realistyczne. Specialty indications (onkologia, rare disease, ATMP) i hot technology areas (AI/ML, radiopharmaceuticals, ADCs) znacznie przyspieszają karierę. Mój Reverse Recruitment pomaga umieścić ruchy academia-to-industry lub specialty pivots.
Często zadawane pytania
Czy potrzebuję PhD do pharma R&D w DACH?
Dla discovery, preclinical i translational research PhD wymagany w 90%+ ról senior. Dla CMC development często magister z doświadczeniem przemysłowym.
Która specjalizacja R&D ma najlepszy wzrost kariery w 2026?
AI/ML w drug discovery, ATMP R&D, radiopharmaceuticals, ADCs, companion diagnostics, translational medicine onkologia/rare disease — 15–25% premium i 30–50% szybsze tempo.
Czy ruch z academia do industry R&D jest realistyczny w DACH 2026?
Tak, zwłaszcza z PhD z Max Planck, Helmholtz, EMBL, ETH plus 1–2 postdocs. Industry postdoc programmes w Roche, Novartis, Bayer, BioNTech są mostami.